Developer docs
API playgroundTry for free, no card

Search company profiles

Polyrizon

Full company profile

uuid0000ko8

Namestring
Polyrizon
Legal namestring
Polyrizon Ltd.
Company typeenum
Public
Founded yearint
2020
Descriptiontext

Polyrizon Ltd. (NASDAQ: PLRZ) is a development-stage biotechnology company headquartered in Ra'anana, Israel, developing intranasal hydrogel products delivered as nasal sprays. The company operates two proprietary platforms: Capture & Contain (C&C), a drug-free polymeric barrier that forms a thin hydrogel shield in the nasal cavity for 3–5 hours per application, marketed under the lead product NASARIX (formerly PL-14) for seasonal allergic rhinitis and the preclinical PL-16 Viral Blocker targeting airborne respiratory viruses; and Trap & Target (T&T), a mucoadhesive polymer platform using sulfated polysaccharides crosslinked with divalent ions to prolong nasal residence time and enable controlled deposition of small molecules, peptides, proteins, and antibodies, applied to an intranasal naloxone candidate (94.6% nasal vestibule/upper turbinate deposition vs. 79.6% for a commercial reference product in a University of Parma cast study) and to a co-developed MEAI neuroplastogen formulation with Clearmind Medicine.

The company is pre-revenue with 1–10 employees, ~$17.5M cash and a debt-free balance sheet at year-end 2025, market capitalization of roughly $21–24M as of June 2026, and a stock price up 136% over the prior year. Capital is sourced via equity — a $17M private placement in March 2025 and a $3.5M registered direct offering in April 2026 — and is being directed toward U.S. multi-center clinical trials for NASARIX (three sites secured with up to five planned, including Texas), EU MDR-compliant human characterization studies, manufacturing scale-up, and IP expansion (published U.S. patent application US 2024/0358741 A1; European application EP 4751737).

Strategic activity in 2026 indicates a directional shift beyond pure biotech: Polyrizon signed non-binding MOUs to acquire 51% of Arrow Aviation Ltd. (private aviation, ~$19M revenue, ~$3M EBITDA, ~$5.8M cash) and to invest up to 20% in Colugo (Israeli eVTOL drones, up to $6M). If consummated, these transactions would convert the listed entity from a single-asset clinical biotech into a hybrid biotech/operating-business holding company — a material change in business model and risk profile that investors should underwrite separately from the core hydrogel pipeline.

Short descriptiontext

Polyrizon is an Israel-based, NASDAQ-listed development-stage biotech developing proprietary intranasal hydrogel nasal sprays (Capture & Contain and Trap & Target platforms) for allergy blocking, viral protection, and drug delivery, with no commercial revenue and a pipeline currently in U.S. and EU clinical studies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersRa'anana, Israel
HQ citystring
Ra'anana
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
intranasal drug delivery, nasal spray medical devices, hydrogel barrier technology, mucoadhesive polymer platforms, allergic rhinitis therapeutics
Industry2 codes
PRIMARYHLAHAIAK
Nasal Drug Delivery Devices (Sprays/Powder Devices)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYCRADAMAG
Eye, Ear & Nasal Care OTC (Eye Drops, Ear Drops/Wax Removal, Saline Sprays)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Health & Hygiene OTC Consumer Goods (First Aid, Oral Care, Personal Health)
NAICS code1 code
  • Urethane and Other Foam Product (except Polystyrene) Manufacturing326150
SIC code1 code
  • Miscellaneous Plastics Products3080
Product category
Intranasal drug delivery and nasal barrier medical devices
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Product Sales (Nasal Spray Medical Devices)
TypeOne Time License
Description

Pre-revenue development-stage company. Anticipated future revenue from commercialization of intranasal hydrogel nasal spray products (NASARIX allergy blocker, PL-16 viral blocker, and naloxone intranasal formulation) as medical devices and/or drug-device combination products following regulatory approval. The global allergic rhinitis treatment market is estimated at $13 billion.

investor.polyrizon-biotech.com
2Platform Licensing and Co-development
TypeLicensing Royalties
Description

Revenue from licensing the Trap & Target mucoadhesive polymer technology platform to pharmaceutical partners for drug delivery applications, as demonstrated by the development agreement with Clearmind Medicine for MEAI intranasal formulation. May include milestone payments and royalties on commercialized products.

in.investing.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1NASARIX
Description

Intranasal allergy blocker product (formerly PL-14) using Capture & Contain hydrogel technology to form a bio-adhesive barrier that physically traps allergens before they reach nasal tissue

investor.polyrizon-biotech.com
+2 more records
Core offering1 text field

Polyrizon develops and commercializes intranasal hydrogel products delivered as nasal sprays for respiratory protection and drug delivery. The company operates two proprietary platforms—Capture & Contain (drug-free physical barrier) and Trap & Target (mucoadhesive drug delivery)—with lead candidates including the NASARIX allergy blocker, PL-16 viral blocker, intranasal naloxone, and a co-developed MEAI CNS formulation.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 94.6% nasal deposition in vestibule and upper turbinate region vs. 79.6% for commercial naloxone reference product
+3 more records
Product overview1 text field

Polyrizon is a development-stage biotech company specializing in innovative intranasal hydrogel products delivered as nasal sprays. The company operates two distinct technology platforms: Capture and Contain (C&C), a barrier protection technology that forms a physical hydrogel shield in the nasal cavity; and Trap and Target (T&T), a mucoadhesive drug delivery platform for enhanced pharmaceutical absorption. The product portfolio includes NASARIX (PL-14), an allergy blocker currently in clinical trials; PL-16 Viral Blocker for respiratory virus protection in pre-clinical development; intranasal naloxone hydrogel for opioid overdose reversal; and an MEAI formulation for CNS disorders developed in partnership with Clearmind Medicine.

Product and service6 records
1NASARIX (PL-14) Allergy Blocker
CategoryCore product — nasal barrier medical device
Description

Intranasal hydrogel allergy blocker spray using Capture & Contain technology to form a bio-adhesive barrier that physically traps airborne allergens before they reach nasal tissue; positioned as a drug-free preventive option for seasonal allergic rhinitis. Currently in U.S. multi-site clinical trials with planned FDA submission.

2PL-16 Viral Blocker
CategoryCore product — nasal barrier medical device
Description

Pre-clinical intranasal product using Capture & Contain hydrogel to form a physical barrier on nasal mucosa, targeting broad-spectrum protection against respiratory viruses including influenza and coronaviruses; pre-clinical data show over 90% cell protection against viruses.

3Intranasal Naloxone Hydrogel
CategoryCore product — intranasal drug-device combination
Description

Intranasal naloxone formulation using Trap & Target technology designed for emergency opioid overdose reversal, demonstrating 94.6% nasal deposition in the vestibule and upper turbinate region vs. 79.6% for a commercial reference product.

4MEAI Intranasal Formulation
CategoryCore product — partnered intranasal drug formulation
Description

Co-developed intranasal formulation of MEAI, a non-hallucinogenic neuroplastogen drug candidate for addiction-related and central nervous system conditions, leveraging Trap & Target technology for enhanced bioavailability and nasal residence time.

5Capture & Contain (C&C) Platform
CategoryPlatform technology — barrier protection
Description

Proprietary hydrogel platform technology made from naturally occurring building blocks that forms a thin shield containment barrier in the nasal cavity, providing 3–5 hours of protection per application against airborne allergens, viruses, and molds by physically blocking and containing biological assaults. Non-irritant, non-drip nasal spray.

6Trap & Target (T&T) Platform
CategoryPlatform technology — intranasal drug delivery
Description

Tunable mucoadhesive polymer platform combining sulfated polysaccharides with hydrophilic polymers crosslinked with divalent ions to create film-forming formulations for intranasal drug delivery. Prolongs nasal residence time, overcomes first-pass metabolism, controls API release kinetics, and prevents dripping; compatible with small molecules, proteins, peptides, and antibodies (corticosteroids, benzodiazepines, naloxone, vaccines, biologics).

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
1European University Medical Center
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-15
Description

Agreement with a leading European university medical center to conduct a human performance and characterization study evaluating the nasal residence time of the NASARIX allergy blocker product. The single-site, non-interventional study involves healthy participants using endoscopic visualization techniques to assess how long the formulation remains in the nasal cavity, supporting Polyrizon's regulatory strategy including planned FDA submissions.

globenewswire.com
2Clinical Research Organization (CRO)
Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2026-06-15
Description

Agreement with a specialized contract research organization (CRO) to conduct a human performance and characterization study for NASARIX evaluating nasal residence time in healthy participants under European regulatory frameworks including MDR (EU) 2017/745 and GCP standards.

globenewswire.com
3U.S. Clinical Trial Sites (Texas and additional locations)
Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2026-05-13
Description

Multi-center clinical trial agreements with U.S. clinical research sites including a first site in Texas and additional strategically selected sites for the NASARIX (PL-14) clinical study in patients with seasonal allergic rhinitis. Three major U.S. clinical trial sites secured with up to five sites planned overall, conducted in accordance with international Good Clinical Practice standards.

globenewswire.com
Strategic tierMinorTypeOthersAnnounced on2026-03-24
Description

Polyrizon intends to acquire up to 20% of Colugo, an Israeli developer of advanced eVTOL drone systems, through a non-binding MOU involving an investment of up to $6 million, expected to close within 7 days of meeting conditions.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-06
Description

Development agreement with Clearmind Medicine Inc. to create a proprietary intranasal formulation of MEAI (5-Methoxy-2-aminoindane), a non-hallucinogenic neuroplastogen drug candidate for addiction-related and central nervous system conditions. Polyrizon applies its intranasal hydrogel technology to enhance MEAI's bioavailability, nasal residence time, and therapeutic efficacy through targeted delivery. The collaboration aims to advance MEAI through clinical development, with Polyrizon's technology designed to bypass first-pass metabolism and offer potentially faster absorption and lower effective doses compared to oral delivery.

Strategic tierMinorTypeOthersAnnounced on2026-02-04
Description

Polyrizon signed a non-binding Memorandum of Understanding to acquire a 51% stake in Arrow Aviation Ltd., a global private aviation company, for approximately $5.8 million in cash (NIS 18M). Arrow Aviation generates annual unaudited revenues of approximately $19 million and adjusted EBITDA of approximately $3 million, operating executive jets for VIP flights, medical evacuations, and hazardous materials cargo services. The agreement includes mutual call and put options on the remaining 49% stake exercisable after two years, potentially enabling Polyrizon to acquire 100% of Arrow Aviation on a fully diluted basis.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Comparative pre-clinical study of Polyrizon's naloxone nasal formulation against a commercial reference product, conducted at the University of Parma's Biopharmanet-TEC research center using a silicone nasal cast model. Polyrizon's formulation achieved 94.6% deposition in the nasal vestibule and upper turbinate region compared to 79.6% for the reference product, demonstrating platform technology's ability to control nasal deposition patterns.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

BD is a major medical device manufacturer with established intranasal drug delivery capabilities including the Prefilled Syringe and nasal delivery franchises. Comparable as a broad incumbent with overlapping nasal device/delivery capability, though diversified across many other product lines.

TypeBroad incumbent
Description

Teva is an Israeli-headquartered global pharmaceutical company with a portfolio of nasal spray products (e.g., allergy and respiratory sprays) and respiratory drug delivery expertise. Comparable as a broad incumbent operating in nasal drug delivery from the same home country as Polyrizon.

TypeBroad incumbent
Description

Perrigo is a leading OTC consumer health company with a portfolio including nasal allergy products (e.g., Prevalin). Comparable as a broad incumbent in the OTC nasal care category where Polyrizon's NASARIX allergy blocker would ultimately compete if commercialized as a consumer device.

TypeBroad incumbent
Description

Emergent BioSolutions manufactures NARCAN, the dominant intranasal naloxone product for opioid overdose reversal. Directly comparable to Polyrizon's intranasal naloxone hydrogel program as the incumbent competitor in that specific application.

TypeBroad incumbent
Description

Aptar Pharma is a leading supplier of nasal drug delivery devices and spray pump systems used across prescription, OTC, and vaccine nasal products. Comparable as a broad incumbent enabling intranasal delivery, though Aptar is primarily a component supplier rather than a therapeutic developer.

TypeDirect peer
Description

Impel Pharmaceuticals develops intranasal drug delivery therapies targeting CNS disorders using its Precision Olfactory Delivery (POD) platform. Highly comparable to Polyrizon's Trap & Target platform for delivering drugs such as MEAI through the nasal route.

TypeEmerging player
Description

Inhalon Biopharma develops iSPERSE, a technology platform for intranasal and inhaled delivery of therapeutics including antivirals. Comparable emerging peer with a focused nasal/inhalation delivery platform intersecting with Polyrizon's viral blocker and drug delivery programs.

TypeEmerging player
Description

Nocion Therapeutics develops 'nocions,' charged local therapeutics that target inflamed or perturbed tissues including airway epithelium. Comparable emerging biotech working on respiratory and nasal drug delivery with novel mechanisms.

TypeEmerging player
Description

AeroRx Therapeutics is developing inhaled and intranasal formulations of known drugs for respiratory and systemic conditions. Comparable emerging player building a pipeline of reformulated drugs using novel nasal/inhaled delivery, similar to Polyrizon's Trap & Target approach.

TypeDirect peer
Description

Neurelis commercialized Valtoco, an intranasal diazepam spray for seizure clusters, leveraging nasal delivery for improved CNS bioavailability. Direct peer in intranasal drug-device combination products targeting CNS indications.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Polyrizon

Intranasal drug delivery and nasal barrier medical devicespolyrizon-biotech.com

Polyrizon is an Israel-based, NASDAQ-listed development-stage biotech developing proprietary intranasal hydrogel nasal sprays (Capture & Contain and Trap & Target platforms) for allergy blocking, viral protection, and drug delivery, with no commercial revenue and a pipeline currently in U.S. and EU clinical studies.

What Polyrizon does

Polyrizon Ltd. (NASDAQ: PLRZ) is a development-stage biotechnology company headquartered in Ra'anana, Israel, developing intranasal hydrogel products delivered as nasal sprays. The company operates two proprietary platforms: Capture & Contain (C&C), a drug-free polymeric barrier that forms a thin hydrogel shield in the nasal cavity for 3–5 hours per application, marketed under the lead product NASARIX (formerly PL-14) for seasonal allergic rhinitis and the preclinical PL-16 Viral Blocker targeting airborne respiratory viruses; and Trap & Target (T&T), a mucoadhesive polymer platform using sulfated polysaccharides crosslinked with divalent ions to prolong nasal residence time and enable controlled deposition of small molecules, peptides, proteins, and antibodies, applied to an intranasal naloxone candidate (94.6% nasal vestibule/upper turbinate deposition vs. 79.6% for a commercial reference product in a University of Parma cast study) and to a co-developed MEAI neuroplastogen formulation with Clearmind Medicine.

The company is pre-revenue with 1–10 employees, ~$17.5M cash and a debt-free balance sheet at year-end 2025, market capitalization of roughly $21–24M as of June 2026, and a stock price up 136% over the prior year. Capital is sourced via equity — a $17M private placement in March 2025 and a $3.5M registered direct offering in April 2026 — and is being directed toward U.S. multi-center clinical trials for NASARIX (three sites secured with up to five planned, including Texas), EU MDR-compliant human characterization studies, manufacturing scale-up, and IP expansion (published U.S. patent application US 2024/0358741 A1; European application EP 4751737).

Strategic activity in 2026 indicates a directional shift beyond pure biotech: Polyrizon signed non-binding MOUs to acquire 51% of Arrow Aviation Ltd. (private aviation, ~$19M revenue, ~$3M EBITDA, ~$5.8M cash) and to invest up to 20% in Colugo (Israeli eVTOL drones, up to $6M). If consummated, these transactions would convert the listed entity from a single-asset clinical biotech into a hybrid biotech/operating-business holding company — a material change in business model and risk profile that investors should underwrite separately from the core hydrogel pipeline.

Polyrizon firmographics

Firmographics
Name
Polyrizon
Legal name
Polyrizon Ltd.
Website
https://polyrizon-biotech.com
Company type
Public
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Short description
Polyrizon is an Israel-based, NASDAQ-listed development-stage biotech developing proprietary intranasal hydrogel nasal sprays (Capture & Contain and Trap & Target platforms) for allergy blocking, viral protection, and drug delivery, with no commercial revenue and a pipeline currently in U.S. and EU clinical studies.
Ownership category
akta.pro rank

Polyrizon industry classification

Industry
Product category
Intranasal drug delivery and nasal barrier medical devices
NAICS
Urethane and Other Foam Product (except Polystyrene) Manufacturing (326150)
SIC
Miscellaneous Plastics Products (3080)
akta.pro industry
PRIMARYHLAHAIAK
Nasal Drug Delivery Devices (Sprays/Powder Devices)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYCRADAMAG
Eye, Ear & Nasal Care OTC (Eye Drops, Ear Drops/Wax Removal, Saline Sprays)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Health & Hygiene OTC Consumer Goods (First Aid, Oral Care, Personal Health)

Keywords

  • Intranasal drug delivery
  • Nasal spray medical devices
  • Hydrogel barrier technology
  • Mucoadhesive polymer platforms
  • Allergic rhinitis therapeutics

Where Polyrizon is headquartered

Location

Headquarters

HQ city
Ra'anana
HQ country
Israel
HQ region
Middle East

Offices1 record

Markets served

Polyrizon business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Product Sales (Nasal Spray Medical Devices): Pre-revenue development-stage company. Anticipated future revenue from commercialization of intranasal hydrogel nasal spray products (NASARIX allergy blocker, PL-16 viral blocker, and naloxone intranasal formulation) as medical devices and/or drug-device combination products following regulatory approval. The global allergic rhinitis treatment market is estimated at $13 billion.
  2. Platform Licensing and Co-development: Revenue from licensing the Trap & Target mucoadhesive polymer technology platform to pharmaceutical partners for drug delivery applications, as demonstrated by the development agreement with Clearmind Medicine for MEAI intranasal formulation. May include milestone payments and royalties on commercialized products.

Go-to-market motion1 record

Marketing channels3 records

Polyrizon product offering

Product offering

Core offering

Polyrizon develops and commercializes intranasal hydrogel products delivered as nasal sprays for respiratory protection and drug delivery. The company operates two proprietary platforms—Capture & Contain (drug-free physical barrier) and Trap & Target (mucoadhesive drug delivery)—with lead candidates including the NASARIX allergy blocker, PL-16 viral blocker, intranasal naloxone, and a co-developed MEAI CNS formulation.

Product overview

Polyrizon is a development-stage biotech company specializing in innovative intranasal hydrogel products delivered as nasal sprays. The company operates two distinct technology platforms: Capture and Contain (C&C), a barrier protection technology that forms a physical hydrogel shield in the nasal cavity; and Trap and Target (T&T), a mucoadhesive drug delivery platform for enhanced pharmaceutical absorption. The product portfolio includes NASARIX (PL-14), an allergy blocker currently in clinical trials; PL-16 Viral Blocker for respiratory virus protection in pre-clinical development; intranasal naloxone hydrogel for opioid overdose reversal; and an MEAI formulation for CNS disorders developed in partnership with Clearmind Medicine.

Differentiator

Problem solved

Functional benefit

Brands

  • NASARIX: Intranasal allergy blocker product (formerly PL-14) using Capture & Contain hydrogel technology to form a bio-adhesive barrier that physically traps allergens before they reach nasal tissue
  • Capture & Contain
  • Trap & Target

Products and services

  • NASARIX (PL-14) Allergy Blocker Intranasal hydrogel allergy blocker spray using Capture & Contain technology to form a bio-adhesive barrier that physically traps airborne allergens before they reach nasal tissue; positioned as a drug-free preventive option for seasonal allergic rhinitis. Currently in U.S. multi-site clinical trials with planned FDA submission.
  • PL-16 Viral Blocker Pre-clinical intranasal product using Capture & Contain hydrogel to form a physical barrier on nasal mucosa, targeting broad-spectrum protection against respiratory viruses including influenza and coronaviruses; pre-clinical data show over 90% cell protection against viruses.
  • Intranasal Naloxone Hydrogel Intranasal naloxone formulation using Trap & Target technology designed for emergency opioid overdose reversal, demonstrating 94.6% nasal deposition in the vestibule and upper turbinate region vs. 79.6% for a commercial reference product.
  • MEAI Intranasal Formulation Co-developed intranasal formulation of MEAI, a non-hallucinogenic neuroplastogen drug candidate for addiction-related and central nervous system conditions, leveraging Trap & Target technology for enhanced bioavailability and nasal residence time.
  • Capture & Contain (C&C) Platform Proprietary hydrogel platform technology made from naturally occurring building blocks that forms a thin shield containment barrier in the nasal cavity, providing 3–5 hours of protection per application against airborne allergens, viruses, and molds by physically blocking and containing biological assaults. Non-irritant, non-drip nasal spray.
  • Trap & Target (T&T) Platform Tunable mucoadhesive polymer platform combining sulfated polysaccharides with hydrophilic polymers crosslinked with divalent ions to create film-forming formulations for intranasal drug delivery. Prolongs nasal residence time, overcomes first-pass metabolism, controls API release kinetics, and prevents dripping; compatible with small molecules, proteins, peptides, and antibodies (corticosteroids, benzodiazepines, naloxone, vaccines, biologics).

Quantifiable outcome

  • 94.6% nasal deposition in vestibule and upper turbinate region vs. 79.6% for commercial naloxone reference product
  • +3 more outcomes

Companies that use Polyrizon

Customer profile

Segments3 records

Ideal customer profiles4 records

Polyrizon technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Polyrizon partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • European University Medical CentercoreStrategic or Co-development Partner · 15 June 2026Agreement with a leading European university medical center to conduct a human performance and characterization study evaluating the nasal residence time of the NASARIX allergy blocker product. The single-site, non-interventional study involves healthy participants using endoscopic visualization techniques to assess how long the formulation remains in the nasal cavity, supporting Polyrizon's regulatory strategy including planned FDA submissions.
  • Clinical Research Organization (CRO)coreImplementation/ SI/ Consulting Partner · 15 June 2026Agreement with a specialized contract research organization (CRO) to conduct a human performance and characterization study for NASARIX evaluating nasal residence time in healthy participants under European regulatory frameworks including MDR (EU) 2017/745 and GCP standards.
  • U.S. Clinical Trial Sites (Texas and additional locations)coreImplementation/ SI/ Consulting Partner · 13 May 2026Multi-center clinical trial agreements with U.S. clinical research sites including a first site in Texas and additional strategically selected sites for the NASARIX (PL-14) clinical study in patients with seasonal allergic rhinitis. Three major U.S. clinical trial sites secured with up to five sites planned overall, conducted in accordance with international Good Clinical Practice standards.
  • ColugominorOthers · 24 March 2026Polyrizon intends to acquire up to 20% of Colugo, an Israeli developer of advanced eVTOL drone systems, through a non-binding MOU involving an investment of up to $6 million, expected to close within 7 days of meeting conditions.
  • Clearmind Medicine Inc.coreStrategic or Co-development Partner · 6 February 2026Development agreement with Clearmind Medicine Inc. to create a proprietary intranasal formulation of MEAI (5-Methoxy-2-aminoindane), a non-hallucinogenic neuroplastogen drug candidate for addiction-related and central nervous system conditions. Polyrizon applies its intranasal hydrogel technology to enhance MEAI's bioavailability, nasal residence time, and therapeutic efficacy through targeted delivery. The collaboration aims to advance MEAI through clinical development, with Polyrizon's technology designed to bypass first-pass metabolism and offer potentially faster absorption and lower effective doses compared to oral delivery.
  • Arrow Aviation Ltd.minorOthers · 4 February 2026Polyrizon signed a non-binding Memorandum of Understanding to acquire a 51% stake in Arrow Aviation Ltd., a global private aviation company, for approximately $5.8 million in cash (NIS 18M). Arrow Aviation generates annual unaudited revenues of approximately $19 million and adjusted EBITDA of approximately $3 million, operating executive jets for VIP flights, medical evacuations, and hazardous materials cargo services. The agreement includes mutual call and put options on the remaining 49% stake exercisable after two years, potentially enabling Polyrizon to acquire 100% of Arrow Aviation on a fully diluted basis.
  • University of Parma (Biopharmanet-TEC)coreStrategic or Co-development PartnerComparative pre-clinical study of Polyrizon's naloxone nasal formulation against a commercial reference product, conducted at the University of Parma's Biopharmanet-TEC research center using a silicone nasal cast model. Polyrizon's formulation achieved 94.6% deposition in the nasal vestibule and upper turbinate region compared to 79.6% for the reference product, demonstrating platform technology's ability to control nasal deposition patterns.

Scale indicators8 records

Recent moves5 records

Expansion highlights6 records

Polyrizon competitors and assessment

Company assessment

Broad incumbents

  • Becton, Dickinson and Company (BD): BD is a major medical device manufacturer with established intranasal drug delivery capabilities including the Prefilled Syringe and nasal delivery franchises. Comparable as a broad incumbent with overlapping nasal device/delivery capability, though diversified across many other product lines.
  • Teva Pharmaceutical Industries: Teva is an Israeli-headquartered global pharmaceutical company with a portfolio of nasal spray products (e.g., allergy and respiratory sprays) and respiratory drug delivery expertise. Comparable as a broad incumbent operating in nasal drug delivery from the same home country as Polyrizon.
  • Perrigo Company: Perrigo is a leading OTC consumer health company with a portfolio including nasal allergy products (e.g., Prevalin). Comparable as a broad incumbent in the OTC nasal care category where Polyrizon's NASARIX allergy blocker would ultimately compete if commercialized as a consumer device.
  • Emergent BioSolutions: Emergent BioSolutions manufactures NARCAN, the dominant intranasal naloxone product for opioid overdose reversal. Directly comparable to Polyrizon's intranasal naloxone hydrogel program as the incumbent competitor in that specific application.
  • Aptar Pharma: Aptar Pharma is a leading supplier of nasal drug delivery devices and spray pump systems used across prescription, OTC, and vaccine nasal products. Comparable as a broad incumbent enabling intranasal delivery, though Aptar is primarily a component supplier rather than a therapeutic developer.

Direct peers

  • Impel Pharmaceuticals: Impel Pharmaceuticals develops intranasal drug delivery therapies targeting CNS disorders using its Precision Olfactory Delivery (POD) platform. Highly comparable to Polyrizon's Trap & Target platform for delivering drugs such as MEAI through the nasal route.
  • Neurelis: Neurelis commercialized Valtoco, an intranasal diazepam spray for seizure clusters, leveraging nasal delivery for improved CNS bioavailability. Direct peer in intranasal drug-device combination products targeting CNS indications.

Emerging players

  • Inhalon Biopharma: Inhalon Biopharma develops iSPERSE, a technology platform for intranasal and inhaled delivery of therapeutics including antivirals. Comparable emerging peer with a focused nasal/inhalation delivery platform intersecting with Polyrizon's viral blocker and drug delivery programs.
  • Nocion Therapeutics: Nocion Therapeutics develops 'nocions,' charged local therapeutics that target inflamed or perturbed tissues including airway epithelium. Comparable emerging biotech working on respiratory and nasal drug delivery with novel mechanisms.
  • AeroRx Therapeutics: AeroRx Therapeutics is developing inhaled and intranasal formulations of known drugs for respiratory and systemic conditions. Comparable emerging player building a pipeline of reformulated drugs using novel nasal/inhaled delivery, similar to Polyrizon's Trap & Target approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

Polyrizon social profiles

Digital presence

Polyrizon financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Polyrizon leadership team

Management profile

Number of profiles

Profiles6 records

Polyrizon subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Polyrizon funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Polyrizon M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Polyrizon

What does Polyrizon do?

Polyrizon develops and commercializes intranasal hydrogel products delivered as nasal sprays for respiratory protection and drug delivery. The company operates two proprietary platforms—Capture & Contain (drug-free physical barrier) and Trap & Target (mucoadhesive drug delivery)—with lead candidates including the NASARIX allergy blocker, PL-16 viral blocker, intranasal naloxone, and a co-developed MEAI CNS formulation.

Is Polyrizon a public or private company?

Polyrizon is a public company. It is classified as public and is currently operating.

When was Polyrizon founded?

Polyrizon was founded in 2020. It employs 1 to 10 people.

Where is Polyrizon based?

Polyrizon is headquartered in Ra'anana, Israel, in the Middle East region.

How does Polyrizon make money?

Two revenue lines are on record. Product Sales (Nasal Spray Medical Devices) is the primary driver. The others are platform Licensing and Co-development.

Who are Polyrizon's main competitors?

Broad incumbents on record are Becton, Dickinson and Company (BD), Teva Pharmaceutical Industries, Perrigo Company, Emergent BioSolutions and Aptar Pharma. Direct peers are Impel Pharmaceuticals and Neurelis. Emerging players are Inhalon Biopharma, Nocion Therapeutics and AeroRx Therapeutics.

Does Polyrizon have an API?

No public API is recorded for Polyrizon.

What industry is Polyrizon in?

Polyrizon's product category is Intranasal drug delivery and nasal barrier medical devices. Its primary akta.pro industry code is HLAHAIAK, Nasal Drug Delivery Devices (Sprays/Powder Devices), with a secondary code of CRADAMAG, Eye, Ear & Nasal Care OTC (Eye Drops, Ear Drops/Wax Removal, Saline Sprays). Its NAICS code is 326150 and its SIC code is 3080.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingPolyrizon Board Adopts Limited-Duration Shareholder Rights PlanPolyrizon's board unanimously adopted a shareholder rights plan effective immediately through November 8, 2027. One special purchase right per ordinary share will be issued on November 19, 2026, exercisable if an acquirer obtains 10% or more without board approval. Shareholders will vote on ratification at the next general meeting.Business & FinancialPOLYRIZON ADOPTS LIMITED DURATION SHAREHOLDER RIGHTS PLANPolyrizon adopted a limited-duration shareholder rights plan effective November 9, 2026, to protect shareholders from open-market accumulation. The plan issues one right per share, exercisable if an acquirer gains 10% or more, and expires November 8, 2027. It will be submitted to shareholders for ratification at the next general meeting.Stock TitanPolyrizon completes enrollment in 120-person NASARIX trialPolyrizon completed enrollment of all 120 planned participants in its U.S. clinical study of NASARIX, an investigational nasal hydrogel for allergic rhinitis. The randomized, controlled trial compares NASARIX with saline control across five sites, with data review expected after treatment and follow-up.American Banking and Market NewsPolyrizon (NASDAQ:PLRZ) Announces Quarterly Earnings ResultsPolyrizon reported Q4 earnings of $0.40 per share. The stock opened at $10.36, with analysts averaging a "Sell" rating. The company develops hydrogel-based nasal products for respiratory protection.The future of tradingPolyrizon enrolls first patient in U.S. trial of NASARIX seasonal allergy nasal sprayPolyrizon began its first U.S. clinical study of NASARIX, a drug-free nasal spray for seasonal allergic rhinitis. The trial enrolls 120 adults across five sites, comparing the spray to saline, with no results presented yet.Stock TitanPolyrizon Enrolls First Patient in NASARIX StudyPolyrizon enrolled the first patient in its U.S. clinical study of NASARIX, an investigational allergy blocker for seasonal allergic rhinitis. The study will randomize 120 patients at five sites to compare NASARIX with saline, evaluating efficacy, safety, and tolerability.CoinMarketCapPolyrizon Ltd. (PLRZ) Stock: Company Closes $4 Million Deal With Institutional Investor: Guest Post by BlockonomiPolyrizon closed a $4 million financing with one institutional buyer on September 4, issuing 232,500 ordinary shares and warrants. The company plans to use net proceeds for working capital and corporate needs. The financing expands its outstanding equity base through new shares and warrant exercises.Quiver QuantitativePolyrizon Ltd. Closes $4 Million Registered Direct Offering and Concurrent Private Placement | PLRZ Stock NewsPolyrizon Ltd. closed a registered direct offering and concurrent private placement, raising approximately $4.0 million from a single institutional investor. The company issued 333,333 Units at $12.00 each, including shares and warrants, with net proceeds for general corporate purposes and working capital.FinancialContent Business PagePolyrizon Ltd. Announces Closing of $4.0 Million Registered Direct Offering and Private PlacementPolyrizon Ltd. closed a registered direct offering and private placement on September 4, 2026, raising approximately $4.0 million from a single institutional investor. The company issued 333,333 units at $12.00 each, including pre-funded and common warrants, and will use proceeds for general corporate purposes and working capital.YahooPolyrizon Ltd. Announces Closing of $4.0 Million Registered Direct Offering and Private PlacementPolyrizon Ltd. closed a registered direct offering and private placement on September 4, 2026, raising approximately $4.0 million. The company issued 333,333 units at $12.00 each, including pre-funded and common warrants. Proceeds will be used for general corporate purposes and working capital.